Development of skeletal muscle atrophy and intermuscular adipose tissue in patients with early breast cancer treated with chemotherapy.
fatty infiltrations
fibro-adipogenic progenitors (FAPs)
intermuscular adipose tissue (IMAT)
muscle architecture
skeletal muscle deconditioning
Journal
American journal of physiology. Cell physiology
ISSN: 1522-1563
Titre abrégé: Am J Physiol Cell Physiol
Pays: United States
ID NLM: 100901225
Informations de publication
Date de publication:
01 Oct 2022
01 Oct 2022
Historique:
pubmed:
13
9
2022
medline:
14
10
2022
entrez:
12
9
2022
Statut:
ppublish
Résumé
Chemotherapy is a common therapy to treat patients with breast cancer but also leads to skeletal muscle deconditioning. Skeletal muscle deconditioning is multifactorial and intermuscular adipose tissue (IMAT) accumulation is closely linked to muscle dysfunction. To date, there is no clinical study available investigating IMAT development through a longitudinal protocol and the underlying mechanisms remain unknown. Our study was dedicated to investigating IMAT content in patients with early breast cancer who were treated with chemotherapy and exploring the subsequent cellular mechanisms involved in its development. We included 13 women undergoing chemotherapy. Muscle biopsies and ultrasonography assessment were performed before and after chemotherapy completion. Histological and Western blotting analyses were conducted. We found a substantial increase in protein levels of three mature adipocyte markers (perilipin, +901%; adiponectin, +135%; FABP4, +321%;
Identifiants
pubmed: 36094434
doi: 10.1152/ajpcell.00373.2022
pmc: PMC9576176
doi:
Substances chimiques
Adiponectin
0
Perilipins
0
Receptor, Platelet-Derived Growth Factor alpha
EC 2.7.10.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
C1325-C1332Références
Front Cell Dev Biol. 2021 Sep 14;9:719643
pubmed: 34595171
EMBO Mol Med. 2013 Apr;5(4):626-39
pubmed: 23505062
Nat Cell Biol. 2018 Aug;20(8):917-927
pubmed: 30050118
FASEB J. 2018 Oct;32(10):5495-5505
pubmed: 29750574
Clin Orthop Surg. 2020 Mar;12(1):76-85
pubmed: 32117542
Cell. 2013 Apr 11;153(2):376-88
pubmed: 23582327
Cell Death Dis. 2014 Apr 17;5:e1186
pubmed: 24743741
Am J Physiol Endocrinol Metab. 2016 Sep 1;311(3):E594-604
pubmed: 27382036
Eur J Appl Physiol. 2004 Aug;92(4-5):602-5
pubmed: 15278355
Chin Med J (Engl). 2013;126(24):4612-7
pubmed: 24342298
J Cachexia Sarcopenia Muscle. 2018 Apr;9(2):335-347
pubmed: 29248005
J Neurol Sci. 1988 Apr;84(2-3):275-94
pubmed: 3379447
J Physiol. 2020 Jul;598(13):2669-2683
pubmed: 32358797
Nat Commun. 2019 Jun 3;10(1):2430
pubmed: 31160583
J Electromyogr Kinesiol. 2014 Apr;24(2):214-20
pubmed: 24485560
Muscle Nerve. 2013 Sep;48(3):393-402
pubmed: 23893872
Open Biol. 2021 Dec;11(12):210110
pubmed: 34875199
Am J Clin Nutr. 2007 Feb;85(2):377-84
pubmed: 17284732
J Cachexia Sarcopenia Muscle. 2022 Jun;13(3):1896-1907
pubmed: 35373507
J Cell Sci. 2011 Nov 1;124(Pt 21):3654-64
pubmed: 22045730
Skelet Muscle. 2014 Nov 27;4:21
pubmed: 25937889
Nat Cell Biol. 2010 Feb;12(2):143-52
pubmed: 20081842
J Pathol. 2016 Dec;240(4):410-424
pubmed: 27569721
Cancer Res. 2020 May 1;80(9):1861-1874
pubmed: 32132110
J Physiol. 2015 Apr 15;593(8):2017-36
pubmed: 25643692
Cardiooncology. 2019 May 03;5:3
pubmed: 32154010
Nat Commun. 2017 Sep 15;8(1):550
pubmed: 28916757
J Am Heart Assoc. 2014 Jan 13;3(1):e000432
pubmed: 24419734
Oncologist. 2020 May;25(5):e852-e860
pubmed: 31951302
Eur J Appl Physiol. 2008 Sep;104(2):401-7
pubmed: 18320207
Sci Rep. 2016 Sep 26;6:32695
pubmed: 27666826
Mol Aspects Med. 2016 Aug;50:56-87
pubmed: 27106402
J Am Acad Orthop Surg. 2013 Oct;21(10):613-23
pubmed: 24084435
Front Cell Dev Biol. 2022 Jan 03;9:790437
pubmed: 35047502
Breast Cancer Res Treat. 2021 Oct;189(3):759-768
pubmed: 34283341